Kantar Health Blog

  • Stephanie Hawthorne
    Oncology Conference Insight: ASCO 2015 --- The treatment armamentarium available for patients with advanced melanoma has become quite well stocked as recent progress in the development of novel therapeutic agents has been tremendous. Immune checkpoint inhibition and targeted inhibition of BRAF and MEK are two therapeutic approaches that have significantly improved survival for patients with advanced melanoma.
    Continue Reading > | Go comment! | Share
  • Stephanie Hawthorne
    Oncology Conference Insight: ASCO 2015 --- Two important drugs obtained FDA approval last year for use in relapsed/refractory chronic lymphocytic leukemia (CLL): Imbruvica® (ibrutinib, Pharmacyclics/Janssen) as a single agent in February 2014 and Zydelig® (idelalisib, Gilead) in combination with Rituxan® (rituximab, Genentech/Roche) in July 2014. Still, better treatment options with greater therapeutic outcomes are strongly needed in CLL treatment in order to prolong survival in these patients.
    Continue Reading > | Go comment! | Share
  • CheckMate? The rules of the game may be changing

    by Arnold DuBell | May 30, 2015
    Arnold DuBell
    Oncology Conference Insight: ASCO 2015 --- Non-small cell lung cancer (NSCLC) is one of the tumor types with the highest unmet need, representing the most commonly diagnosed cancer globally and one that is frequently diagnosed at an advanced stage, where prognosis is most dire. As such, NSCLC has long been a focus of significant clinical development and currently is a poster child of personalized medicine – treatment varies significantly depending on a patient’s tumor histology and their biomarker status.
    Continue Reading > | Go comment! | Share
  • Stephanie Hawthorne
    The annual meeting of the American Society of Clinical Oncology (ASCO) is nearing, and Kantar Health has identified several pivotal abstracts that will be presented. The 2015 ASCO annual meeting promises to be packed with the latest data and trends from the world of oncology, and the meeting has the potential to alter treatment practices in several tumor types.
    Continue Reading > | Go comment! | Share
  • Stephanie Hawthorne
    Oncology Conference Insight: ASCO GU --- Surgical resection is the primary treatment for patients with early-stage renal cell carcinoma (RCC) and can potentially be curative in up to 70% of cases. In many solid tumors, patients at high risk of recurrence are often treated with adjuvant (postsurgical) systemic therapy, with the idea being to eradicate any microscopic residual disease and thus decrease the likelihood of developing a local or metastatic recurrence.
    Continue Reading > | Go comment! | Share